Longevity Pipeline
Shift Bioscience
Reprogramming w/o dedifferentiation · Aging
PreclinicalPartial Epigenetic Reprogramming
Mechanism
Reprogramming w/o dedifferentiation
Intervention class
Discovery / epigenetic
Indication
Aging
Stage
Preclinical
Evidence
invitro
Funding
VC-backed
Backers
Various
Overview
Aging-clock-guided search for single factors that rejuvenate cells while avoiding the cancer risk of full reprogramming. Cambridge-based.
Technology
Shift Bioscience works in Partial Epigenetic Reprogramming — Rewinding a cell's biological age without erasing what it is.
Read the Partial Epigenetic Reprogramming brief →Related companies
Altos Labs
Partial epigenetic reprogramming
Retro Biosciences
Reprogramming, autophagy, plasma factors
Life Biosciences
Partial reprogramming (OSK via AAV)
NewLimit
Epigenetic reprogramming (factor discovery)
Rejuvenate Bio
Gene therapy (FGF21, sTGFβR2, klotho); reprogramming
Turn Biotechnologies
mRNA epigenetic reprogramming
Company website / source ↗ Open the interactive map →
◢ Boom-cycle briefing
Get ahead of the next biotech boom.
New companies, stage changes, deal alerts and fresh tech briefs — one sharp email when the map moves.
Curated biotech intelligence, compiled for orientation — not investment advice. Company stages, deals and figures move fast; verify against ClinicalTrials.gov, company filings and primary sources before acting.